← 홈

프로그램 비교

타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일

현재 선택: 1개 · 임상 갱신 필요 1개

프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.

프로그램 선택

API CSV28행 · 1개 프로그램
OverviewMoAPK/PDToxicologyClinicalPreclinical

표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.

항목
AntibodyLimited DatastalePhase 2
ASCT (Autologous Stem Cell Transplant, Autologous Stem Cell Transplant (ASCT))
Amgen·Multiple Myeloma
186 trials
Overview
Program
Autologous Stem Cell Transplant (ASCT)
Overview
Company
Amgen
Overview
Modality
ANTIBODY
Overview
Target
Multiple Myeloma
Overview
Indication
Multiple Myeloma
Overview
Phase
PHASE_2
Overview
Status
RECRUITING
Overview
Content status
Limited Data
Overview
Data Confidence
Data Confidence · Low
Overview
Development Signal
Development Signal · Emerging
Overview
Approval status
Investigational
MoA
Mechanism
targeting DM-sensitive antigen
MoA
Biomarker
biomarker of disease biology
PK/PD
Species
Mouse
PK/PD
Animal (cat.)
Mouse
PK/PD
Experiment
PD
Toxicology
Species
Mouse
Toxicology
Animal (cat.)
Mouse
Toxicology
Major finding
thrombocytopenia, anemia, neutropenia and febrile neutropenia
Toxicology
CRS
Reported
Clinical
Safety signal
thrombocytopenia, anemia, neutropenia and febrile neutropenia
Clinical
Reported PFS
46.2
Clinical
Reported OS
79.2
Clinical
Result source
ClinicalTrials.gov NCT01208662
Clinical
Program phase
PHASE_2
Clinical
Trial activity
No active/completed counts
Clinical
Trial ref
NCT01208662
Preclinical
Animal (cat.)
Mouse